Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Abstract Treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) may attenuate kidney disease progression and cardiovascular events but their real-world impact on healthcare utilization and mortality in this population are not well-defined
Samoilov, M., Plyasunov, S
This range minimizes surface adsorption losses while keeping injection volumes reasonable and measurement errors acceptable
Review and comparison of neuromuscular and central nervous system manifestations of hyperthyroidism in cats and humans
Zhou, S., Dai, W., Zhong, G
US$ 29.75
US$ 25.08
US$ 25.93
